Nektar Therapeutics (NKTR) revenue breakdown
By product, Non-cash royalty revenue related to the sales of future royalties is the largest at 99% of fiscal 2025 revenue, growing 7% a year over 9 years.
Revenue by product
Fiscal years, as Nektar Therapeutics reports them in its 10-K filings; fiscal 2025 total $55M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-cash royalty revenue related to the sales of future royalties | $30M | $31M | $33M | $36M | $49M | $78M | $70M | $69M | $64M | $55M | 99% |
| License, collaboration and other revenue | $60M | $211M | $1.1B | $17M | $56M | $436,000 | $2M | $520,000 | $597,000 | $300,000 | 1% |
| Product sales | $55M | $33M | $21M | $20M | $18M | $24M | $20M | $21M | $34M | — | — |
| Royalty revenue | $20M | $34M | $42M | $41M | — | — | — | — | — | — | — |
| Royalty revenue | — | — | — | — | $31M | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for NKTR.
Open NKTR in InvestinglyQuestions
Where does Nektar Therapeutics make its money?
In fiscal 2025, by product: Non-cash royalty revenue related to the sales of future royalties $55M, License, collaboration and other revenue $300,000.
From Nektar Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.